

Ref. No: 0299
Date: 04/10/23
Subject: Intra-vitreous treatments for eye conditions

REQUEST

1. For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab – Lucentis
- Ranibizumab – Ongavia

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab – Lucentis
- Ranibizumab – Ongavia

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as this request relates to historic data we have provided the response in two sections relating to the hospital sites of each of the legacy organisations.

1. For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Intra-Vitreous Injections / Implants	No. of Administrations
Aflibercept	709
Bevacizumab - Avastin	0
Bevacizumab - Biosimilar	0
Brolucizumab	10

Dexamethasone	33*
Faricimab	154
Ranibizumab – Lucentis (pre-filled syringes)	622
Ranibizumab – Lucentis (vials)	0
Ranibizumab – Ongavia	<5**

* This figure does not include data from the Pharmacy Department at Southport and Ormskirk Hospital NHS Trust, as usage figures are not recorded i.e. Pharmacy supply a kit for preparation, with intra-vitreous dexamethasone made up on the ward.

** Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Intra-Vitreous Injections / Implants	No. Patients
Aflibercept	62
Bevacizumab - Avastin	0
Bevacizumab - Biosimilar	0
Brolucizumab	0
Dexamethasone	<5***
Faricimab	12
Ranibizumab – Lucentis (pre-filled syringes)	36
Ranibizumab – Lucentis (vials)	0
Ranibizumab – Ongavia	0

*** Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.